As Pparγ upstream factors such as CDK5 are considered as new molecular targets for insulin resistance and other metabolic diseases, mechanism studies of these compounds may provide new molecular targets for obesity and obesity-related metabolic diseases [31,32]. The gene discussed is CDK5; the disease is Other metabolic disease.